编者按：慢性髓系白血病（CML）是白血病中进展相对缓慢的一种类型。然而一旦疾病进展至急变期，患者的预后将急剧恶化。最近20多年，一系列靶向疗法的涌现正帮助CML患者延长生命。作为全球医药创新的赋能者，药明康德一直以来依托“一体化、端到端”的CRDMO ...

At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with ...

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the ...

Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...

This was not the first presentation on STI-571, but it was the one that would change everything: The New England Journal of ...

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

MONTREAL, Dec. 10, 2025 /CNW/ - Novartis Canada is pleased to announce that Scemblix ® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario's new Funding ...